

Editor
MALCOLM S. M. WATTS, M.D.

Associate Editor
LLOYD H. SMITH, JR., M.D.

Managing Editor
ROBERT F. EDWARDS
For information on preparation of
manuscript, see advertising page 2

Policy Committee—Editorial Board

MALCOLM C. TODD, M.D., Long Beach
ALBERT G. MILLER, M.D., San Mateo
WILLIAM F. QUINN, M.D., Los Angeles
JOSEPH F. BOYLE, M.D., Los Angeles
RICHARD S. WILBUR, M.D., Palo Alto
HELEN B. WEYRAUCH, M.D.,
San Francisco
MALCOLM S. M. WATTS, M.D.,
San Francisco

**California
Medicine**



EDITORIAL

Welcome AMA

CALIFORNIA MEDICINE welcomes the American Medical Association to San Francisco for its 117th Annual Convention. This welcome is a warm one and it is not only to San Francisco but to all of California and the West. You have come periodically since 1871 and have watched us wrestle with our growth and our problems. Your initial California convention, also in San Francisco, was held soon after the transcontinental railroads were completed. It proved to be a potent stimulus to organized medicine in California which has been restlessly growing and generally thriving since that occasion.

The editors of CALIFORNIA MEDICINE and the Council of the California Medical Association take pleasure in presenting this special issue of our Journal as a gift to physician registrants at this AMA convention in San Francisco. While each issue of this monthly Journal strives to reflect the increasingly important scientific, socio-economic and political achievements of medicine in the West, and also to discuss constructively many other scientific and social problems which remain yet to be resolved, this particular number has been especially structured to provide informative and useful fare for physicians who have come from everywhere, and who would perhaps like to take another reading on what's going on in California and the West — as well as attend the convention. If there

are moments between meetings, or perhaps enroute home, when this June issue profitably occupies your interest, the editors and staff will be well rewarded.

CALIFORNIA MEDICINE, it should also be noted, has made another and much greater gift not only to the physicians who may attend this convention, but to all of American medicine. Its editor for twenty-one years has resigned that post and he is missed. He will be inaugurated the 123rd President of the American Medical Association at this meeting in San Francisco.

We wish the AMA a happy and productive convention and Dwight L. Wilbur particular Godspeed as he assumes his enormous responsibility.

A New Kind of Forum

A NEW KIND of forum is inaugurated elsewhere in this issue. It is a forum with a practical purpose which goes beyond the usual exchange of views, and sometimes emotion, which all too often leads to little or nothing except occasionally a feeling of relief or satisfaction on the part of some of the participants. The purpose of the forum on "The Scope and Responsibility of Medicine" (page 405) is to provide a means of relatively free discussion of a topic which badly needs discussion, within a framework which is not sharply restricted as to time, place or participants, and which is capable of producing an end product distilled from the discussion which might achieve formal acceptance and so be useful.

The scope and responsibility of medicine in present day society is such a topic. Until this can be identified and at least somewhat defined, it is unlikely if not impossible that rational or meaningful programming for any aspect of health education or health care can take place. The problem is first to bring interested and informed opinion to bear, provide for interaction and exchange, and then identify the threads which run through the discussion, and eventually try to weave them into some sort of fabric which will receive general approval and acceptance. It is only when a problem is well defined and a clear question is asked that a correct answer can be found.

If the forum on "The Scope and Responsibility of Medicine" can achieve its purpose it will also demonstrate the usefulness of a new technique in the decision making process within a democratic human institution. This could be its greatest contribution.

Current Knowledge of Psoriasis

ANY DISEASE WHICH may affect between 200,000 and 600,000 persons in the United States is an important one. Although psoriasis is considered benign in the sense that it is not significant as a cause of death, it most certainly is not benign in the socio-economic sense. An old synonym, *lepra alphas*, apparently stems from biblical times when psoriasis probably was frequently mistaken for leprosy. In any event, psoriasis is a dread, loathsome disease which, in the words of Sulzberger, more frequently ruins the reputation of the dermatologist than any other dermatosis, with the possible exception of warts. It is quite unpredictable and capricious, and the tendency is life-long.

Elsewhere in this issue is a superlative review of current knowledge of psoriasis by Farber and McClintock. It is a testimonial to the productivity of the broadly based research program at Stanford Medical School. Such an article cannot be encyclopedic (several hundred articles and monographs are published on the subject each year), but it does contain a balanced and critical summary of the pertinent information now available concerning this important disease.

The review accurately reflects that we have no

startling new facts about psoriasis. It has been known for a long time, on the basis of excellent studies in Germany, Denmark and this country, that the disease has strong genetic overtones, and it is well established that psoriasis consists of an increased epidermopoiesis. Curiously, the only non-cutaneous component thus far described is psoriatic arthritis, unless one includes Reiter's syndrome as being a variant of psoriasis. It is a disease, however, in which there may be systemic repercussions, as for example the hypervolemia and increased cardiac output which may complicate generalized erythroderma and exfoliation, even leading to cardiac decompensation.

Drs. Farber and McClintock tell us of newer understanding of traditional topical treatments (including the dangers thereof) and point out that the use of topical corticosteroids is not without hazard. As for systemic treatment, the beneficial effect of inorganic arsenic has been recognized for at least a century, coupled with awareness of serious drawbacks, principally the delayed onset of malignant change. Systemic corticosteroids have a place occasionally in the treatment of severe psoriasis but must be employed with critical judgment and control. Methotrexate and other chemotherapeutic agents developed for the management of malignant disease may be of aid in highly selected cases as suppressive, non-specific therapy.

The authors point out that no explanation for the pathogenesis of psoriasis is as yet at hand. The possibility of an enzyme defect is appealing in this era of molecular diseases, but no substantial information exists in support of this. Even if the genetic pattern were more clearly delineated, there is as yet no particular metabolic pathway which can be implicated.

Farber and his colleagues have made a significant contribution in characterizing the disease more clearly and in assessing and evaluating its natural history. The etiology and pathogenesis of psoriasis still elude us. While this remains true, therapy will continue to be empirical.

Routine Chemical Screening

IN RECENT YEARS routine screening for asymptomatic disease has assumed a prominent role in the